Navigation Links
Catalent to Discuss the Future of Cell and Gene Therapy Manufacturing at World Orphan Drug Congress Europe
Date:11/5/2019

Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products, today announced it will present at the upcoming World Orphan Drug Congress Europe, being held at Hotel Sofia, Barcelona, Spain on Nov. 12 – 14, 2019.

On Wednesday, Nov. 13 at 3:20 p.m., Philip Wills, Ph.D., Chief Commercial Officer, Paragon Gene Therapy (part of Catalent Biologics) will present “Capacity Crunch? The Future of Manufacturing Within Cell & Gene Therapy” as part of the manufacturing track. Dr. Wills’ presentation will highlight the challenges that the gene therapy sector faces in scale-up and manufacturing, driven by the rising numbers of clinical trials and FDA approvals, coupled with low product yields and rising treatment costs. These factors have led to an increased demand for process expertise and manufacturing capacity, and Dr. Wills will address the capacity limitations and discuss the future of cell and gene therapy manufacturing.

Also, on Wednesday, at 2:20 p.m., Stephen Tindal, Director, Science & Technology and Gavin Yates, Program Director, Clinical Supply Services and Drug Product Technologies Integrations, will discuss the benefits of contracting with a single, integrated provider in their presentation, “Next Exit, Success: Get from Concept to Clinic Faster on the Product Development Superhighway.” In the presentation, Mr. Tindal and Mr. Yates will highlight opportunities to streamline and shorten product development timelines.

Dr. Wills has almost two decades of contract manufacturing experience, primarily focused in viral vectors and other complex biologics. He joined Paragon in 2002 where he has since held positions of increasing scope and responsibility, including as Principal Scientist and Vice President of Business Development. He received a bachelor’s degree in chemistry from John Hopkins University, Baltimore, Maryland, and a doctorate in pharmacology from University of Maryland Medical School, Maryland.

Mr. Tindal has worked in softgel R&D for more than 30 years and has broad expertise in this technology. He specializes in root cause investigation, technology innovation, gelatin innovation, and plays a key role in customer liaison and supporting business development. Mr. Tindal holds a bachelor’s degree in chemistry and analytical science from Loughborough University, U.K.

Mr. Yates has more than 15 years’ experience in the pharmaceutical industry. His areas of expertise include project management, packaging and labeling, operational activity, supply chain management and key performance indicator (KPI) analysis. He received his bachelor’s degree in biological sciences from University of Birmingham, U.K.

For more information, visit https://www.catalent.com/index.php/news-events/events/World-Orphan-Drug-Congress-Europe.

To arrange a meeting with any of the attending Catalent experts at the event, contact Richard Kerns at NEPR - richard@nepr.agency.

About Catalent
Catalent is the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, gene therapies, and consumer health products. With over 85 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable global clinical and commercial product supply. Catalent employs nearly 13,000 people, including over 2,400 scientists and technicians, at more than 35 facilities, and in fiscal year 2019 generated over $2.5 billion in annual revenue. Catalent is headquartered in Somerset, New Jersey. For more information, visit http://www.catalent.com.

More products. Better treatments. Reliably supplied.™

Read the full story at https://www.prweb.com/releases/catalent_to_discuss_the_future_of_cell_and_gene_therapy_manufacturing_at_world_orphan_drug_congress_europe/prweb16695271.htm.


'/>"/>
Source: PRWeb
Copyright©2019 Vocus, Inc.
All rights reserved


Related biology news :

1. Catalent to Present Case Studies on Formulation Design for Early Phase Molecules and Discuss Benefits of Mass Spectrometry for HCP Analysis at AAPS PharmSci 360
2. Catalent Announces the Appointment of David Schaffer to Biologics Advisory Board
3. Catalent to Launch OneBio Suite for Integrated Biologics Development, Manufacturing and Supply at BIO International 2019
4. Planning for Orphan Drug Supply to be Discussed by Catalent at World Orphan Drug Congress
5. Catalent Receives P&G External Business Partner of the Year Award
6. Biopharma Leaders to Discuss and Share Insights on the Regional Biopharma Ecosystem at LeadingBiotech’s NY/NJ CEO Conference
7. Biopharma Leaders Convene to Discuss Topics in Biotech, Healthcare and Innovation at LeadingBiotech’s Inaugural South CEO Conference
8. Greenberg Traurig Hosts Boston Healthcare Drinks and Discussion on China Biopharma Industry
9. Cell Signaling Technology Discusses Challenges and Opportunities of Post-translational Modifications and Data-Independent Acquisitions in Educational Webinar
10. DiaSorin Furthers the Discussion on HDV, the Most Severe Form of Viral Hepatitis, in Educational Webinar
11. STEM Initiatives in Grade School are Discussed on "On Demand" with Rob Lowe
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2020)... PHOENIX (PRWEB) , ... July 03, 2020 , ... ... is proud to earn outstanding recognition and multiple awards for not only the ... the ABM portfolio, SoME® Skincare and Vivace® Microneedle RF. All the brands built ...
(Date:6/28/2020)... ... June 25, 2020 , ... ... software solutions for biopharmaceutical R&D, today announced that it has entered into ... full-length multispecific antibodies (Multiclonics®), to support their translational and clinical research strategy ...
(Date:6/23/2020)... ... 2020 , ... The field of quantitation of large molecules or proteins has ... area. However, the use of mass spectrometry in this field has gained a lot ... do you choose which approach to use (LBA or MS)?” In many cases, ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... ... July 29, 2020 , ... The SDX® ... in 16 countries, has reached its 20th anniversary of worldwide use. Introduced in ... at top universities including University of Pennsylvania, University of Michigan, University of Maryland, ...
(Date:7/18/2020)... MILWAUKEE (PRWEB) , ... July 16, 2020 , ... “We ... at Third Wave Bioactives. “It’s the only technology of its kind on the market ... flavor of onions with the protective capacity of traditional cultured ingredients, creating a natural ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... Technology (MIT) has expanded the company’s exclusive license to include clinical applications ... point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast ...
(Date:7/7/2020)... ... 2020 , ... Bio-IT World has announced the winners of ... University of Chicago, Massachusetts General Hospital, Mission: Cure, and the Pistoia Alliance were ... outstanding examples of how technology innovations and strategic initiatives can be powerful forces ...
Breaking Biology Technology: